Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study.
暂无分享,去创建一个
I. Macdougall | F. Locatelli | R. Vanholder | A. Więcek | A. Covic | B. Canaud | P. Aljama | A. D. De Francisco